Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 840.35 INR -1.56% Market Closed
Market Cap: ₹150.5B

Relative Value

The Relative Value of one NATCOPHARM stock under the Base Case scenario is hidden INR. Compared to the current market price of 840.35 INR, Natco Pharma Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NATCOPHARM Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

NATCOPHARM Competitors Multiples
Natco Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Natco Pharma Ltd
NSE:NATCOPHARM
150.5B INR 3.4 9.8 6.5 7.6
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.5 56.6 38 40.7
US
Johnson & Johnson
NYSE:JNJ
560.6B USD 6 21.1 14.7 18
CH
Roche Holding AG
SIX:ROG
287.9B CHF 4.7 30.7 12.9 15.1
UK
AstraZeneca PLC
LSE:AZN
215.3B GBP 5.1 31.6 15.1 22.1
US
Merck & Co Inc
NYSE:MRK
296.3B USD 4.6 15.6 11 13.1
CH
Novartis AG
SIX:NOVN
229.6B CHF 5.3 20.5 12.9 16.6
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.2 10.6
US
Pfizer Inc
NYSE:PFE
148.6B USD 2.4 15.6 7.8 10.7
FR
Sanofi SA
PAR:SAN
98.2B EUR 1.8 8.3 7.7 7.7
P/E Multiple
Earnings Growth PEG
IN
Natco Pharma Ltd
NSE:NATCOPHARM
Average P/E: 22.3
9.8
-23%
N/A
US
Eli Lilly and Co
NYSE:LLY
56.6
54%
1
US
Johnson & Johnson
NYSE:JNJ
21.1
6%
3.5
CH
Roche Holding AG
SIX:ROG
30.7
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.6
38%
0.8
US
Merck & Co Inc
NYSE:MRK
15.6
14%
1.1
CH
Novartis AG
SIX:NOVN
20.5
17%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
2%
6.6
US
Pfizer Inc
NYSE:PFE
15.6
27%
0.6
FR
Sanofi SA
PAR:SAN
8.3
1%
8.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Natco Pharma Ltd
NSE:NATCOPHARM
Average EV/EBITDA: 42.6
6.5
-29%
N/A
US
Eli Lilly and Co
NYSE:LLY
38
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.7
2%
7.3
CH
Roche Holding AG
SIX:ROG
12.9
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
15.1
10%
1.5
US
Merck & Co Inc
NYSE:MRK
11
6%
1.8
CH
Novartis AG
SIX:NOVN
12.9
6%
2.1
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
1%
9.2
US
Pfizer Inc
NYSE:PFE
7.8
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Natco Pharma Ltd
NSE:NATCOPHARM
Average EV/EBIT: 90.7
7.6
-33%
N/A
US
Eli Lilly and Co
NYSE:LLY
40.7
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
18
6%
3
CH
Roche Holding AG
SIX:ROG
15.1
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
22.1
23%
1
US
Merck & Co Inc
NYSE:MRK
13.1
8%
1.6
CH
Novartis AG
SIX:NOVN
16.6
12%
1.4
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
0%
N/A
US
Pfizer Inc
NYSE:PFE
10.7
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3